Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Beijing Tong Ren Tang Chinese Medicine Co ( (HK:3613) ) has shared an announcement.
Beijing Tong Ren Tang Chinese Medicine Company Limited has signed a renewed master lease framework agreement with its controlling shareholder, Tong Ren Tang Holdings, to secure the continued leasing of premises used for production and operations from 1 January 2026 to 31 December 2028. The arrangement, which allows group entities to amend or renew existing leases for offices, warehouses and staff quarters within agreed annual caps, is classified as a continuing connected transaction and an asset acquisition under Hong Kong listing rules and HKFRS 16, triggering reporting, announcement and annual review requirements but exempting it from independent shareholders’ approval; this framework helps provide operational stability while underscoring the company’s reliance on related-party property arrangements.
The most recent analyst rating on (HK:3613) stock is a Hold with a HK$9.50 price target. To see the full list of analyst forecasts on Beijing Tong Ren Tang Chinese Medicine Co stock, see the HK:3613 Stock Forecast page.
More about Beijing Tong Ren Tang Chinese Medicine Co
Beijing Tong Ren Tang Chinese Medicine Company Limited is a Hong Kong–incorporated company engaged in the production and operation of traditional Chinese medicine products and related healthcare services. The company operates within the broader Tong Ren Tang Group, leveraging shared premises such as offices, warehouses and staff quarters to support its manufacturing and commercial activities worldwide.
Average Trading Volume: 1,007,751
Technical Sentiment Signal: Sell
Current Market Cap: HK$7.26B
For a thorough assessment of 3613 stock, go to TipRanks’ Stock Analysis page.